A meta-analysis of lipid peroxidation markers in major depression

Código QR

A meta-analysis of lipid peroxidation markers in major depression

Graham Mazereeuw,1,2 Nathan Herrmann,1,3 Ana C Andreazza,2–4 Maisha M Khan,1 Krista L Lanctôt1–3 1Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 2Department of Pharmacology and Toxicology, Universi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3ed4a0d0636b4b17a50f1096de2ab5cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study
por: Mazereeuw G, et al.
Publicado: (2015)

Kynurenine and depressive symptoms in a poststroke population
por: Bensimon K, et al.
Publicado: (2014)

Desvenlafaxine in the treatment of major depressive disorder
por: Maria Teresa C Lourenco1, et al.
Publicado: (2009)

Psychiatric comorbidities in patients with major depressive disorder
por: Thaipisuttikul P, et al.
Publicado: (2014)

Transcranial magnetic stimulation for the treatment of major depression
por: Janicak PG, et al.
Publicado: (2015)

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
por: Han Y, et al.
Publicado: (2016)

The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression
por: Dannehl K, et al.
Publicado: (2014)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Mazen K Ali, et al.
Publicado: (2011)

Augmentation treatment in major depressive disorder: focus on aripiprazole
por: J Craig Nelson, et al.
Publicado: (2008)

Mitochondrial dysfunction, oxidative stress, and major depressive disorder
por: Tobe EH
Publicado: (2013)

The cortisol awakening response and major depression: examining the evidence
por: Dedovic K, et al.
Publicado: (2015)

Levomilnacipran for the treatment of major depressive disorder: a review
por: Asnis GA, et al.
Publicado: (2015)

Is placebo useful in the treatment of major depression in clinical practice?
por: Marchesi C, et al.
Publicado: (2013)

Psychomotor retardation and externally oriented thinking in major depression
por: Luca M, et al.
Publicado: (2013)

Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review
por: Chen YW, et al.
Publicado: (2015)

Synaptic proteins in CSF relate to Parkinson’s disease stage markers
por: Erika Bereczki, et al.
Publicado: (2017)

Major depressive disorder: mechanism-based prescribing for personalized medicine
por: Saltiel PF, et al.
Publicado: (2015)

Anatomical and functional brain abnormalities in unmedicated major depressive disorder
por: Yang X, et al.
Publicado: (2015)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak J, et al.
Publicado: (2013)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang XF, et al.
Publicado: (2015)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez E, et al.
Publicado: (2014)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

Serum lipid profile among sporadic and familial forms of Parkinson’s disease
por: Daniel Macías-García, et al.
Publicado: (2021)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

Shared genetic etiology between Parkinson’s disease and blood levels of specific lipids
por: Helena Xicoy, et al.
Publicado: (2021)

Major depressive disorders in chronic hemodialysis patients in Nazareth: identification and assessment
por: Armaly Z, et al.
Publicado: (2012)

Getting the balance right: Established and emerging therapies for major depressive disorders
por: Bojana Perovic, et al.
Publicado: (2010)

Age-associated decrease in global DNA methylation in patients with major depression
por: Tseng PT, et al.
Publicado: (2014)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
por: Pecenak J, et al.
Publicado: (2013)

“Hot cross bun” is a potential imaging marker for the severity of cerebellar ataxia in MSA-C
por: Shuzhen Zhu, et al.
Publicado: (2021)

Cilostazol for secondary stroke prevention: systematic review and meta-analysis
por: Leonard LL Yeo, et al.
Publicado: (2021)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima K, et al.
Publicado: (2013)

Recurrent major depression, ataxia, and cardiomyopathy: association with a novel POLG mutation?
por: Verhoeven WMA, et al.
Publicado: (2011)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
por: Baskaran A, et al.
Publicado: (2013)

Subthalamic and pallidal deep brain stimulation for Parkinson’s disease—meta-analysis of outcomes
por: M. Lenard Lachenmayer, et al.
Publicado: (2021)

Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis
por: Jia-Hung Chen, et al.
Publicado: (2021)

Association between toll-like receptor 4 expression and symptoms of major depressive disorder
por: Wu MK, et al.
Publicado: (2015)

Differential clinical effects of fluvoxamine by the effect of age in Japanese female major depressive patients
por: Hisashi Higuchi, et al.
Publicado: (2009)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
por: Kamijima K, et al.
Publicado: (2013)

Neutrophil–lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy
por: Demir S, et al.
Publicado: (2015)